1. Home
  2. CFND vs IXHL Comparison

CFND vs IXHL Comparison

Compare CFND & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CFND

C1 Fund Inc.

N/A

Current Price

$5.31

Market Cap

36.5M

Sector

N/A

ML Signal

N/A

Logo Incannex Healthcare Inc.

IXHL

Incannex Healthcare Inc.

HOLD

Current Price

$0.45

Market Cap

49.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CFND
IXHL
Founded
N/A
2001
Country
Australia
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
36.5M
49.1M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
CFND
IXHL
Price
$5.31
$0.45
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
N/A
23.6M
Earning Date
N/A
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$12,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
N/A
$0.08
52 Week High
N/A
$2.25

Technical Indicators

Market Signals
Indicator
CFND
IXHL
Relative Strength Index (RSI) N/A 64.33
Support Level N/A $0.35
Resistance Level N/A $0.50
Average True Range (ATR) 0.00 0.03
MACD 0.00 0.02
Stochastic Oscillator 0.00 80.58

Price Performance

Historical Comparison
CFND
IXHL

About CFND C1 Fund Inc.

C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.

About IXHL Incannex Healthcare Inc.

Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

Share on Social Networks: